Page 9 - சமூகம் க்கு நோயெதிர்ப்பு சிகிச்சை ஆஃப் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Poseida Therapeutics Announces Carl June, M D , to Chair Immuno-Oncology Scientific Advisory Board
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results
March 17, 2021 GMT
DARTMOUTH, Nova Scotia (BUSINESS WIRE) Mar 17, 2021
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year ended December 31, 2020.
“Notwithstanding the challenges everyone faced in 2020, IMV’s commitment to provide effective and well-tolerated immunotherapies to patients with hard-to-treat cancer resulted in significant progress on multiple fronts with our lead compound, Maveropepimut-S, and with other DPX-based candidates,” said Fred Ors, Chief Executive Officer at IMV Inc. “We see 2021 as a transformational year for IMV as we are advancing Maveropepimut-S in both relapsed, refractory DLBC
IMV Inc (IMV) Q4 2020 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.
First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders.
Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million).
Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business .
Shattuck Labs, Inc.March 15, 2021 GMT
– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –
– Dose-escalation data from Phase 1 clinical trial for lead partnered PD-1 checkpoint inhibitor, SL-279252 (PD1-Fc-OX40L), expected in the second half of 2021 –
AUSTIN, TX and DURHAM, NC, March 15, 2021 (GLOBE NEWSWIRE) Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided r
vimarsana © 2020. All Rights Reserved.